International journal of hematology-oncology and stem cell research最新文献

{"title":"Evaluation of Vimentin as a Marker of Cervical Carcinogenesis in Women Infected with Human Papillomavirus and <i>Chlamydia trachomatis</i> with Cervical Pathology.","authors":"S J Magaji, M Aminu, Mhi Doko, O A Oguntayo, Ahmed Sa, J D Yaro, M A Abubakar, K O Sani, V G Nelson, O E Alaba","doi":"10.18502/ijhoscr.v19i3.19286","DOIUrl":"10.18502/ijhoscr.v19i3.19286","url":null,"abstract":"<p><p><b>Background</b>: Among the co-factors contributing to human papillomavirus (HPV)-related cervical carcinogenesis, genital chlamydial infection is considered a very strong risk factor. The molecular mechanisms by which this organism contributes to HPV-related cervical carcinogenesis remain unknown. This study aimed to evaluate the role of vimentin in cervical carcinogenesis in women infected with human papillomavirus and <i>Chlamydia trachomatis.</i> <b>Materials and Methods:</b> A total of 200 formalin-fixed paraffin-embedded (FFPE) cervical tissue samples were collected from women with pre-invasive and invasive cervical disease in northern Nigeria during July 2022 to September 2023. Samples were screened for both high-risk human papillomavirus (hrHPV) and <i>C. trachomatis</i> antigen using GeneXpert^® and rapid tests, respectively. Samples that were positive for hrHPV, <i>C. trachomatis</i>, and cervical cancer underwent immunohistochemistry assay for vimentin detection. <b>Results</b>: The results showed that 47 (23.5%) samples had hrHPV, while 17 (8.5%) samples had <i>C. trachomatis</i> antigen. A total of 103 samples were assayed for vimentin expression, of which 16 (15.5%) samples expressed vimentin at varying degrees. It was observed that vimentin expression increased significantly with increasing tumor severity. <b>Conclusion</b>: The strong statistical association between vimentin expression and hrHPV-<i>C. trachomatis</i> co-infection in cervical carcinogenesis suggests the potential application of vimentin expression assays for early detection of cervical cancer, monitoring disease progression, and implementing prompt treatment approaches. This study findings implicate epithelial-mesenchymal transition (EMT) as a possible molecular mechanism for cervical carcinogenesis in women infected with hrHPV and <i>C. trachomatis</i> and highlight vimentin as a poor prognostic indicator, given its observed correlation with tumor severity.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 3","pages":"223-236"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12630380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145590419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appraising Treatment for Gastrointestinal Stromal Tumors of the Wild-Type Mutation in the Setting of NF1: A Case Report.","authors":"Darshan Gundala, Rachel Hae-Soo Joung, Amy Wells, Ashley Hardy, John Abad, Akhil Chawla","doi":"10.18502/ijhoscr.v19i3.19292","DOIUrl":"10.18502/ijhoscr.v19i3.19292","url":null,"abstract":"<p><p>Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms that can occur anywhere in the GI tract, but commonly present in the stomach and small bowel. Here we present a 39-year-old male with a suspected GIST in the setting of type I neurofibromatosis (NF1). Given the history of NF1 and presumable insensitivity to Imatinib, surgical oncology opted for resection of the mass after discussion with the multidisciplinary sarcoma tumor board. Instead of neoadjuvant therapeutic options for wild-type (WT) NF1-related GIST, surgical resection remains the most advantageous treatment. The efficacy of tyrosine kinase inhibition and other chemotherapies tailored for WT GIST is currently untenable and warrants increased clinical trials and exploration of WT pathogenesis concerning NF1 to support Imatinib-sensitive patients.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 3","pages":"296-302"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12630393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145590400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunocytochemical Detection of BCL-2 Protein in Chronic B-Cell Lymphoproliferative Disorders.","authors":"Awad-Elkareem Abass, Isra O Babiker, Alaa G Mohmmed, Remaz A Hamza, Salma A Albashir, Ohood K Osman, Safa A Abbas, Amna M Idris","doi":"10.18502/ijhoscr.v19i3.19283","DOIUrl":"10.18502/ijhoscr.v19i3.19283","url":null,"abstract":"<p><p><b>Background:</b> The expression of anti-apoptotic B-cell lymphoma 2 (BCL-2) protein in B-cell chronic lymphoproliferative disorders (B-CLPDs) can provide valuable prognostic information and assist in assessing minimal bone marrow (BM) infiltration. This study aimed to detect BCL-2 expression in B-CLPDs and correlate the findings with various clinicobiologic factors. <b>Materials and Methods:</b> Immunocytochemical staining was performed on mononuclear cell smears from 46 Sudanese patients, including 25 with B-cell chronic lymphocytic leukaemia (B-CLL) and 21 with B-cell non-Hodgkin's lymphomas (B-NHL), who were enrolled during their visit to the Radiation and Isotope Centre and Fedail Hospital, Khartoum. Diagnosis was based on clinical examination, morphology, and immunophenotyping. <b>Results:</b> Among the 46 B-CLPD cases, BCL-2 expression was identified in 13 (28.2%), including 8/25 (32%) cases with B-CLL and 5/21 (23.8%) with B-NHL. No statistically significant associations were found between BCL-2 expression and age, sex, total white blood cell count, disease stage, and serum lactate dehydrogenase levels (all P>0.05). However, BM involvement was significantly associated with BCL-2 expression (P=0.02). <b>Conclusion:</b> The immunocytochemical staining method effectively detects BCL-2 protein in B-CLPDs, even in cases with minimal BM infiltration, thereby facilitating the correlation of this protein's expression with morphological and other clinicobiologic features. By combining cytologic morphology with immunocytochemistry, this technique enables earlier and more accessible evaluation of BM involvement.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 3","pages":"210-214"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12630390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145590489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Engraftment Kinetics of Neutrophils and Platelets in Peripheral Blood Stem Cells Transplant Patients in a Quaternary Care Centre.","authors":"Elamathi Manoharan, Thulasi Raman Ramalingam, Revathy Raj, Lakshman Vaidhyanathan","doi":"10.18502/ijhoscr.v19i3.19284","DOIUrl":"10.18502/ijhoscr.v19i3.19284","url":null,"abstract":"<p><p><b>Background:</b> This study aimed to evaluate the rate of neutrophil and platelet engraftment in pediatric hematopoietic stem cell transplant (HSCT) patients. Additionally, it sought to assess whether engraftment kinetics were influenced by CD34+ cell dose, CD3+ cell dose in T cell-replete transplants with post-transplant cyclophosphamide (PTCy), and the type of stem cell transplantation. <b>Materials and Methods:</b> The study included 60 pediatric patients undergoing hematopoietic stem cell transplantation between August 2023 and January 2024. Flow cytometry was used to quantify CD34+ cells. A peripheral smear and the haematology analyzer were used to measure the platelet count and neutrophils from day 1+ to day 28+. <b>Results:</b> Among 60 patients, 3 were autologous (5%), 15 were MRD (25%), 6 were MUD (10%), 30 were T-cell-repleted transplants with PTCy (50%), and 6 were TCRα/β-depleted transplants (10%). The neutrophil and platelet engraftment were correlated with demographic characteristics (e.g., age and gender) and clinical factors (e.g., transplant, diagnosis, and CD34+ cell dosage levels). In addition, CD3+ T cell dosages of ≥2×108 cells/kg or < 2×108 cells/kg were also correlated with engraftment kinetics. Both the type of peripheral blood stem cell transplant (PBSCT) and the CD3+ T cell dose showed a statistically significant association with neutrophil engraftment. <b>Conclusion:</b> This study showed a poor correlation between CD34+ cell dosage and engraftment. However, maximum engraftment occurred between day 10+ and day 14+ in fully matched transplants. T cell-repleted transplants with PTCy exhibited maximum engraftment between 15-18 days, and all TCR α/β depleted transplants engrafted between day 10+ and day 14+.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 3","pages":"215-222"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12630374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145590422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergic Treatment of Plant-Based Antioxidants with Iron Chelators for Iron Overload in Transfusion-Dependent-Thalassemia Patients: A Systematic Review.","authors":"Moe Thida Kyaw, Phyu Synn Oo, Afshan Sumera, Anupa Sivakumar, Carolina Santiago, Yin Nwe Aung","doi":"10.18502/ijhoscr.v19i3.19289","DOIUrl":"10.18502/ijhoscr.v19i3.19289","url":null,"abstract":"<p><p>The combined use of plant-based antioxidants and iron chelators presents a synergistic treatment approach that effectively tackles both iron overload and the accompanying oxidative stress in individuals with transfusion-dependent Thalassemia (TDT). Plant-based antioxidants counteract reactive oxygen species (ROS) and oxidative damage, whereas iron chelators effectively bind excess iron, reducing the body's iron concentration. This combined therapy can be beneficial in improving TDT patients with iron overload. We systematically reviewed the literature exploring the plant-based antioxidants with iron chelators for iron overload in transfusion-dependent Thalassemia Patients. All fourteen included studies were randomized clinical trials, employing various randomization methods including simple randomization, double-blinded, triple-blinded, and crossover designs. The included studies enrolled participants across different age groups, including both young and adult patients. Despite the variability in plant-based antioxidants with iron-chelating properties, the key findings were as follows: Nine studies reported a significant reduction in iron overload, eight studies observed a marked decrease in oxidative stress markers, and five studies demonstrated reduced liver enzyme levels, suggesting potential hepatoprotective effects. All included studies reported significant effects of various supplements on key biomarkers, including total iron (Fe), ferritin, total iron-binding capacity (TIBC), total antioxidant capacity (TAC), malondialdehyde (MDA), and liver enzymes (AST, ALT). Silymarin, green tea, and grape seed extract (GSE) supplementation demonstrated notable reductions in total Fe, Ferritin, ASL, and ALT levels. Additionally, these supplements increased TIBC levels, suggesting improved iron metabolism. In contrast, quercetin and curcumin supplementation did not show a statistically significant difference compared to control groups in these outcomes.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 3","pages":"261-285"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12630495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145590561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rare Case of Autoimmune Hemolytic Anemia in Pancreatic Adenocarcinoma.","authors":"Soniya Abraham, Sana Sultana, Jay Parekh","doi":"10.18502/ijhoscr.v19i3.19294","DOIUrl":"10.18502/ijhoscr.v19i3.19294","url":null,"abstract":"<p><p>Autoimmune hemolytic anemia (AIHA) is the immune-mediated destruction of red blood cells leading to anemia. It is a well-known paraneoplastic syndrome in hematological malignancies, particularly lymphoproliferative disorders but rarely reported in solid tumors. In this report, we describe the case of a 79-year-old gentleman who presented with mixed AIHA, initially treated with methylprednisolone and rituximab, resulting in laboratory improvement. CT abdomen and pelvis showed a 3.6 cm pancreatic tail mass concerning for neoplasm with splenic vein thrombosis and carcinomatosis. The biopsy revealed pancreatic adenocarcinoma. Methylprednisolone was changed to prednisone and his hemoglobin remained stable throughout the hospital course. This case presents an extremely rare association between AIHA and pancreatic adenocarcinoma.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 3","pages":"307-309"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12630395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145590213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rare Case of Bone Marrow Infiltration of Disseminated Medulloblastoma in a Young Adult.","authors":"Ruchee Khanna, Nithya Roopa Prem, Vishwapriya Mahadev Godkhindi, V Geeta","doi":"10.18502/ijhoscr.v19i3.19293","DOIUrl":"10.18502/ijhoscr.v19i3.19293","url":null,"abstract":"<p><p>Medulloblastoma is the most common primary CNS malignant neoplasm in the paediatric age group, accounting for 12 to 20 % of all childhood malignancies, but medulloblastoma in an adult is rare. We report a case of a 31-year-old male who presented with an inability to walk and episodic vomiting. MRI of the brain revealed a midline lesion involving the vermis and cerebellar hemispheres. Excision and immunohistochemistry confirmed the diagnosis of medulloblastoma, desmoplastic/nodular. After 10 months, he had a recurrence of the tumour and a redo surgery was attempted, followed by 6 # cycles of chemotherapy. The patient was lost to follow-up; 3 years later, PET-CT showed multiple metastases to the lung and cervical lymph node along with bicytopenia. The bone marrow study revealed interstitial infiltration by small round blue cells. Immunohistochemistry showed these cells were positive for synaptophysin, supporting a diagnosis of medulloblastoma metastasis to the bone marrow.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 3","pages":"303-306"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12630538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145590394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evans Syndrome: Analysis of 1255 Adult Cases in US Hospitals, Revealing Demographics, Associations, and Outcomes.","authors":"Rushin Patel, Mrunal Patel, Fehmida Laxmidhar, Darshil Patel, Zalak Patel, Safia Shaikh, Khushboo Lakhatariya","doi":"10.18502/ijhoscr.v19i2.18546","DOIUrl":"10.18502/ijhoscr.v19i2.18546","url":null,"abstract":"<p><p><b>Background:</b> Evans syndrome (ES) is a rare immune disorder characterized by immune thrombocytopenia and warm autoimmune hemolytic anemia (wAIHA), with the possibility of autoimmune neutropenia (AIN). Limited data due to its rarity led us to perform a descriptive analysis of demographics, outcomes, and comorbidities. <b>Materials and Methods:</b> This study used the National Inpatient Sample database to identify Evans syndrome hospitalizations (ICD-10 code D69.41) from 2016 to 2019, with national estimates. We collected demographic data, examined outcomes, and assessed patient comorbidity. STATA Version 17 was used for data analysis. <b>Results:</b> In our study of 1,255 ES hospitalizations, the mean age was 50.13 years, with a relatively even gender distribution. The racial breakdown included White (59.6%), Black (17.1%), and Hispanic (14.6%). Most had Medicare (41.8%), Medicaid (20.4%), or private insurance (33.5%). Charlson Comorbidity Index scores varied, with 36.6% scoring 3 or more. Non-elective admissions accounted for 90.2% of cases, coming from various U.S. Census Divisions, with East North Central (16.2%) and Pacific (16.1%) leading. Large urban teaching hospitals handled 84.1% of cases. Mortality was 5.5%, the mean stay was 7.8 days, with total charges averaging $114,696. Notable associations included SLE (15.63%), ITP (37%), and anemia (53.5%). Inpatient risks included AKI (22.47%) and sepsis (15.33%). Interventions included red blood cell transfusion (18.65%) and platelet transfusion (10.44%). <b>Conclusion:</b> This study offers key insights into ES in hospitalized adults, emphasizing demographic trends and important associations with other conditions. More research is required to enhance our understanding of ES and enhance outcomes for those affected.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 2","pages":"93-100"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12368710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy.","authors":"Saasha Vinoo, Divya Jaiswal, Palak Mehta, Atharv Battu, Anuradha Majumdar","doi":"10.18502/ijhoscr.v19i2.18555","DOIUrl":"10.18502/ijhoscr.v19i2.18555","url":null,"abstract":"<p><p>The plethora of advancements in cancer treatment has resulted in designing unique signatures and personalized therapies, tailored to patient-specific needs, using medications that target specific markers on cancer cells or even retrain the body's immune system. Chimeric Antigen Receptor T-cell, also called as CAR T-cell, is one such approach wherein a patient's cells are modulated to kill the cancer cells. Conventional cancer treatments invite issues like low specificity, increased chances of relapse, or issues with radiotoxicity and tolerance in the case of chemotherapy. Currently, CAR T-cell therapy is under clinical investigation, and different countries are still coming up with their guidelines for the pragmatic application of CAR T. In this review, we present all one needs to know about CAR T-cell therapy, its types, components, side effects, current authorization status in different countries, along with the technology being used in the therapy. We also briefly upon the recent regulations or guidelines released by Europe and the USA, the countries that have actively initiated the CAR T idea. This review aims to provide insight into this targeted therapy, which has the potential to boost cancer research and to help researchers develop more such patient-specific treatments to improve clinical outcomes in cancer.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 2","pages":"180-190"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12368713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prognostic Value of C-Reactive Protein and Albumin in Newly Diagnosed Patients with AML.","authors":"Nasrin Namdari, Sezaneh Haghpanah, Elahe Ataie, Fateme Ghanbarian, Maral Mokhtari, Mahya Amini","doi":"10.18502/ijhoscr.v19i2.18547","DOIUrl":"10.18502/ijhoscr.v19i2.18547","url":null,"abstract":"<p><p><b>Background</b>: Acute-phase reactant proteins, particularly C-reactive protein (CRP), play a critical role in the initiation, progression, and recurrence of cancers such as acute myeloid leukemia. <b>Materials and Methods:</b> We retrospectively analyzed 127 newly diagnosed non-M3 acute myeloblastic leukemia (non-M3 AML) patients. We investigated pre-treatment levels of C-reactive protein (CRP), Albumin, and C-reactive protein to albumin ratio (CAR) with cytogenetics, response to induction therapy, recurrence, and overall survival. <b>Results:</b> We did not find any relationship between levels of CRP, Albumin, and C-reactive protein to albumin ratio (CAR) with complete remission rate, recurrence, and risk categorization of patients (P > 0.05). 3-and 5- year overall survival was 40.8% (with a standard error of 4.7%) and 30.1% (standard error: 5.3%), respectively. In addition, 3-year and 5-year event-free survival was 31.3% (standard error = 4.4%) and 25.8% (standard error = 4.8%), respectively. The only prognostic factor was allogenic stem cell transplantation (SCT). <b>Conclusion:</b> Although CRP, Albumin, and CAR serve as convenient prognostic markers, they were not predictive of overall survival (OS) and event-free survival (EFS) in AML patients. Further studies are needed in the future to confirm or refute our results.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 2","pages":"101-108"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12368717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}